Literature DB >> 2647186

Respiratory virus infection in immunocompromised patients.

P Ljungman1, C A Gleaves, J D Meyers.   

Abstract

Seventy-eight immunocompromised patients were prospectively evaluated for infection with respiratory viruses including parainfluenza viruses, respiratory syncytial virus, influenza viruses and adenoviruses beginning before marrow transplant and continuing to 60 days after transplant or discharge from hospital. Patients were studied both on a fixed surveillance schedule and at any time upper or lower respiratory symptoms developed. Fifteen (19%) patients had a respiratory virus detected including parainfluenza 1 in six patients, adenovirus in five, parainfluenza 3 in two, and influenza A and respiratory syncytial virus in one each. Twelve patients had infection before transplant and 11 of these had upper respiratory symptoms. Three patients had virus isolated only after transplant. Both patients with parainfluenza 3 infection developed pneumonia. One patient died with disseminated adenovirus infection. These data suggest that infections with respiratory viruses are frequent and often symptomatic in immunocompromised patients. Since antiviral therapy is available for some of these infections, early specific viral diagnosis is of potential clinical importance in immunocompromised patients with respiratory symptoms.

Entities:  

Mesh:

Year:  1989        PMID: 2647186

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  24 in total

1.  Amelioration of established Sendai viral pneumonia in the nude mouse using a monoclonal antibody to the virus fusion protein.

Authors:  P Carthew; J Riley; D Dinsdale
Journal:  Br J Exp Pathol       Date:  1989-12

2.  Viral findings during febrile episodes after cytotoxic chemotherapy in patients with hematological malignancies.

Authors:  E M Rintala; J Nikoskelainen; T Ziegler; R Jussila
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-08       Impact factor: 3.267

3.  Adenovirus: current epidemiology and emerging approaches to prevention and treatment.

Authors:  Uriel Sandkovsky; Luciano Vargas; Diana F Florescu
Journal:  Curr Infect Dis Rep       Date:  2014-08       Impact factor: 3.725

4.  Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies.

Authors:  Rodrigo Martino; Rocío Parody Porras; Nuria Rabella; John V Williams; Elena Rámila; Nuria Margall; Rosa Labeaga; James E Crowe; Pedro Coll; Jorge Sierra
Journal:  Biol Blood Marrow Transplant       Date:  2005-10       Impact factor: 5.742

5.  Crystals of hemagglutinin-neuraminidase of parainfluenza virus contain triple-stranded helices.

Authors:  K G Murti; T Takimoto; W G Laver; A Portner
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-15       Impact factor: 11.205

Review 6.  Mixed viral infections: detection and management.

Authors:  J L Waner
Journal:  Clin Microbiol Rev       Date:  1994-04       Impact factor: 26.132

Review 7.  Adenoviruses in immunocompromised hosts.

Authors:  Marcela Echavarría
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

8.  Respiratory virus pneumonia after hematopoietic cell transplantation (HCT): associations between viral load in bronchoalveolar lavage samples, viral RNA detection in serum samples, and clinical outcomes of HCT.

Authors:  Angela P Campbell; Jason W Chien; Jane Kuypers; Janet A Englund; Anna Wald; Katherine A Guthrie; Lawrence Corey; Michael Boeckh
Journal:  J Infect Dis       Date:  2010-05-01       Impact factor: 5.226

9.  Antigenic relationships among the 47 human adenoviruses determined in reference horse antisera.

Authors:  J C Hierholzer; Y O Stone; J R Broderson
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

Review 10.  The challenge of respiratory virus infections in hematopoietic cell transplant recipients.

Authors:  Michael Boeckh
Journal:  Br J Haematol       Date:  2008-09-10       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.